Market Overview - The Hang Seng Index rose by 0.46%, gaining 119 points to reach 26,013 points, while the Hang Seng Tech Index increased by 0.51%. The morning trading volume in Hong Kong was HKD 114 billion [1] Company Performance - Meituan-W (03690) saw a morning increase of 5.85%, while Alibaba indicated a significant reduction in investment for Taobao Flash Sale expected in the next quarter [1] - Eastern Airlines (00670) experienced a rise of over 6%, benefiting from improved oil cost management [1] Biotechnology Sector - The Hang Seng Biotechnology Index increased by over 2%. Rongchang Biotech (09995) rose by over 5%, and Kangfang Biotech (09926) increased by over 4%. China Biopharmaceutical (01177) rose by 2.59% due to a significant breakthrough in HER2 dual-target ADC for breast cancer treatment [2] - Junshi Biosciences (01877) also saw an increase of over 3% as it plans to submit for listing following the successful Phase III clinical trial of Toripalimab subcutaneous injection [2] Other Notable Stocks - Basilea Pharmaceutica-B (02616) rose by over 6% after the European Commission approved a new indication for Sugliquin [3] - GDS Holdings (09698) increased by nearly 4% due to improved supply of domestic AI chips, with Morgan Stanley expecting a surge in orders in the second half of next year [3] - Longi Green Energy (06869) rose by nearly 7%, driven by interest in Google's TPU chips, with institutions optimistic about growth driven by AI data communication [3] - Smoore International (06969) increased by over 4% after signing a long-term procurement agreement for battery cells with EVE Energy to secure supply for its e-cigarette products [3] Alibaba Financial Results - Alibaba-W (09988) experienced a decline of over 2% during trading, with its adjusted net profit for the second fiscal quarter dropping by 72% year-on-year [4]

Market Overview - The Hang Seng Index increased by 0.46%, gaining 119 points to reach 26,013 points, while the Hang Seng Tech Index rose by 0.51%. The morning trading volume in Hong Kong was HKD 114 billion [1]. Airline Sector - Airline stocks led the gains, with China Eastern Airlines (00670) rising over 6% due to improved oil cost dynamics benefiting airline performance [2]. Biotechnology Sector - The Hang Seng Biotechnology Index rose over 2%. Rongchang Biopharmaceutical (09995) increased by over 5%, and Kangfang Biotech (09926) rose over 4%. China Biopharmaceutical (01177) gained 2.59% following significant breakthroughs in its self-developed HER2 dual-target ADC for breast cancer. Junshi Biosciences (01877) also saw an increase of over 3% as its Toripalimab subcutaneous injection Phase III clinical trial met its primary endpoint, with plans for subsequent listing application [3]. Pharmaceutical Sector - Basilea Pharmaceutica (02616) rose over 6% after the European Commission approved a new indication for Sugliquide [4]. AI and Technology Sector - GDS Holdings (09698) increased nearly 4% as domestic AI chip supply improved, with Morgan Stanley projecting a surge in orders by the second half of next year [5]. - Changfei Optical Fiber (06869) rose nearly 7% due to increased interest in Google's TPU chips, with institutions optimistic about AI-driven growth. Smoore International (06969) gained over 4% after signing a long-term battery cell procurement agreement with EVE Energy to secure supply for its electronic cigarette products [6]. E-commerce Sector - Alibaba Group (09988) saw a decline of over 2% during trading, with its adjusted net profit for the second fiscal quarter dropping 72% year-on-year [7].

Group 1 - The Hang Seng Index rose by 0.46%, gaining 119 points to close at 26,013 points, while the Hang Seng Tech Index increased by 0.51%. The morning trading volume in Hong Kong reached HKD 114 billion [1] - Meituan-W (03690) saw a morning increase of 5.85%, while Alibaba indicated a significant reduction in investment for Taobao Flash Sale expected in the next quarter [1] - Airline stocks performed well, with China Eastern Airlines (00670) rising over 6% due to improved oil cost benefits for airline performance [1] Group 2 - The Hang Seng Biotechnology Index increased by over 2%, with Rongchang Biologics (09995) rising over 5% and Kangfang Biologics (09926) up over 4% [2] - China Biopharmaceutical (01177) rose by 2.59% after its subsidiary achieved a significant breakthrough in HER2 dual-target ADC for breast cancer [2] - Junshi Biosciences (01877) increased by over 3% as its Toripalimab subcutaneous injection Phase III clinical trial met its primary endpoint, with plans for subsequent listing application [2] - Basilea Pharmaceutica-B (02616) rose over 6% after the European Commission approved a new indication for Sugliumab [2] - GDS Holdings Limited-SW (09698) increased by nearly 4% as domestic AI chip supply improves, with Morgan Stanley expecting a surge in orders in the second half of next year [2] Group 3 - Changfei Optical Fiber (601869) and Optical Cable (06869) rose nearly 7%, driven by interest in Google's TPU chips, with institutions optimistic about AI-driven growth in data communication [3] - Smoore International (06969) increased by over 4% after signing a long-term procurement agreement for battery cells with EVE Energy (300014) to secure supply for electronic cigarette products [3] - Alibaba-W (09988) fell over 2% as its adjusted net profit for the second fiscal quarter decreased by 72% year-on-year [3]

Group 1 - Vitasoy International (00345) reported a 6% year-on-year decrease in revenue and a 7% decrease in gross profit for the six months ending September 30, 2025, primarily due to weak market conditions in mainland China [1] - Shandong Xinhua Pharmaceutical (00719) saw a rise of over 2% after receiving approval from the National Medical Products Administration for the registration of a drug [1] - China Biologic Products (01177) increased by over 2% following the publication of positive Phase II clinical trial results for TQB2102 in HER2-positive breast cancer in a prestigious journal [1] - GDS Holdings (09698) rose over 4% after reporting a net income of 2.887 billion RMB for Q3, a 10.2% year-on-year increase, and a net profit margin of 25.2% [1] Group 2 - GaYa Optical (00907) surged by 49.12% after announcing a profit forecast of 8.8 million to 9.6 million HKD for the six months ending September 30, 2025, a significant turnaround from a loss of 13.8 million HKD in the same period last year [2] - Green Leaf Pharmaceutical (02186) rose nearly 2% after announcing FDA approval for clinical trials of a new drug [2] - Hengrui Medicine (01276) increased by over 5% after receiving approval for clinical trials of two drugs [2] - Meituan-W (03690) saw a 6% rise as Alibaba's CFO announced increased investment in Taobao Flash Purchase [2] Group 3 - Alibaba Group (09988) experienced a nearly 2% drop after reporting a 5% year-on-year revenue increase for Q2, but a significant 78% decline in adjusted EBITA [3] - Junshi Biosciences (01877) rose nearly 4% after announcing successful Phase III trial results for a drug in treating non-small cell lung cancer [4] Group 4 - Abercrombie & Fitch (ANF.US) surged by 37.54% after reporting Q3 earnings that exceeded expectations with an adjusted EPS of $2.36 and a 7% year-on-year sales increase [5] - Symbotic (SYM.US) rose by 39.36% after reporting Q4 revenue of $618 million despite a net loss [5] - Novo Nordisk (NVO.US) increased by 4.65% following positive results for a new weight loss and diabetes drug [5] - Kohl's (KSS.US) saw a 42.53% increase after exceeding Q3 earnings expectations and raising full-year guidance [6] - Alibaba (BABA.US) rose by 2.31% after reporting a 5% year-on-year revenue increase, although adjusted net profit fell by 72% [6] - Pony.ai (PONY.US) increased by 5.88% after announcing profitability for its seventh-generation Robotaxi [6]

Core Viewpoint - The recent financial performance of the company shows a positive trend, with significant revenue growth and strategic initiatives to enhance liquidity and support future expansion in AI-related infrastructure [1] Financial Performance - The company reported a net income of 2.8871 billion RMB for the third quarter, representing a year-on-year growth of 10.2% [1] - The net profit for the quarter was 728.6 million RMB, with a net profit margin of 25.2% [1] Strategic Initiatives - The company successfully issued the first public REITs for data centers in the country, generating approximately 2.248 billion RMB in net cash proceeds, which effectively bolstered its liquidity [1] - The additional funds are aimed at supporting business expansion, technology research and development, and the construction of AI-related infrastructure [1] Market Outlook - Bank of America Securities noted that the decline in data center construction costs is expected to maintain resilient internal rates of return for new projects, driven by strong AI demand projected to boost orders significantly by 2026 [1] - JPMorgan anticipates an acceleration in orders in the second half of 2026, primarily due to improved supply of domestic AI chips, with about 65% of new orders in 2025 expected to be AI-related, potentially leading to double-digit revenue growth in 2027 [1] - The company's international business and core customer commitments for electricity consumption remain robust [1]

Core Viewpoint - The recent financial performance of the company shows a positive growth trajectory, driven by strategic initiatives and strong demand in the AI sector [1] Financial Performance - The company reported a net income of 2.8871 billion RMB for the third quarter, representing a year-on-year growth of 10.2% [1] - The net profit for the same period was 728.6 million RMB, with a net profit margin of 25.2% [1] Strategic Initiatives - The company successfully issued the first public REITs for data centers in the country, generating approximately 2.248 billion RMB in net cash proceeds [1] - This capital infusion is aimed at enhancing liquidity for future business expansion, technology research and development, and AI-related infrastructure projects [1] Market Outlook - Bank of America Securities anticipates that the decline in data center construction costs will maintain resilient internal rates of return for new projects, with strong order growth expected driven by AI demand by 2026 [1] - JPMorgan forecasts an acceleration in orders in the second half of 2026, primarily due to improved supply of domestic AI chips, with about 65% of new orders in 2025 being AI-related, potentially leading to double-digit revenue growth in 2027 [1] - The company's international business and core customer commitments for electricity consumption remain robust [1]

Core Viewpoint - The recent financial performance of GDS Holdings Limited (万国数据-SW) shows a positive trend with significant revenue growth and strategic financial maneuvers to support future expansion [1] Financial Performance - For the third quarter, GDS reported a net revenue of 2.8871 billion RMB, representing a year-on-year increase of 10.2% [1] - The net profit for the same period was 728.6 million RMB, with a net profit margin of 25.2% [1] Strategic Initiatives - The company successfully issued the first public REITs for data centers in the country, generating approximately 2.248 billion RMB in net cash proceeds, which enhances liquidity for future business expansion, technology development, and AI infrastructure [1] Market Outlook - Bank of America forecasts that the decline in data center construction costs will maintain resilient internal rates of return for new projects, driven by strong AI demand expected to boost orders significantly by 2026 [1] - JPMorgan anticipates an acceleration in orders in the second half of 2026, primarily due to improved supply of domestic AI chips, with about 65% of new orders in 2025 related to AI, potentially leading to double-digit revenue growth in 2027 [1] - The international business and commitments from core customers regarding electricity purchase volumes remain robust [1]

Core Viewpoint - GDS Holdings (GDS.US) experienced a pre-market decline of over 1.5%, trading at $33, following a report from JPMorgan indicating that the company's Q3 performance was largely in line with expectations, including a one-time gain from the spin-off of data centers to C-REIT [1] Group 1 - JPMorgan's report suggests that GDS's Q3 results met the bank's expectations, which included a one-time gain from the data center spin-off [1] - Management anticipates challenges in 2026 due to weaker-than-expected new order performance since Q2 of this year, and potential further declines in Monthly Service Revenue (MSR) as existing contracts are renewed [1] - JPMorgan has lowered its price target for GDS's U.S. stock from $46 to $40 while maintaining an "Overweight" rating [1]

Core Viewpoint - GDS Holdings (GDS.US) shares fell over 1.5% pre-market, trading at $33, following a report from JPMorgan indicating that the company's Q3 performance was in line with expectations, including a one-time gain from the spin-off of data centers to C-REIT [1] Financial Performance - The Q3 results were generally in line with JPMorgan's expectations, which included a one-time gain from the data center spin-off [1] - Management anticipates challenges in 2026 due to weaker-than-expected new order performance since Q2 of this year [1] Revenue Outlook - Monthly Service Revenue (MSR) may decline further as existing contracts are renewed [1] - JPMorgan has lowered the target price for GDS shares from $46 to $40 while maintaining an "Overweight" rating [1]

Market Overview - The US stock market saw all three major indices rise, with the Dow Jones up 0.44% to 46,448.27 points, the S&P 500 up 1.55% to 6,705.12 points, and the Nasdaq up 2.69% to 22,872.01 points, led by gains in Merck and Amazon, both rising over 2% [12][11] - In the European market, the DAX index increased by 0.71% to 23,255.92 points, while the CAC40 and FTSE 100 indices fell by 0.29% and 0.05%, respectively [12][11] - The Hang Seng Index in the Asia-Pacific region rose by 1.97% to 25,716.5 points, while the Nikkei 225 index fell by 2.40% to 48,625.88 points [12][11] Domestic News - China's foreign direct investment increased by 4.4% year-on-year in the first three quarters, totaling 923.68 billion yuan, maintaining its position as the third-largest global investor [15] - High-tech industry sales revenue grew by 13.6% year-on-year in October, with significant growth in integrated circuits, industrial robots, and unmanned manufacturing [16] - The People's Bank of China will conduct a 1 trillion yuan MLF operation on November 25, marking the ninth consecutive month of increased liquidity support [14] Company News - Xiaomi Group's founder Lei Jun increased his stake by purchasing 2.6 million shares, raising his ownership to 23.26% [20] - Apple has made rare layoffs in its sales department, affecting several positions [20] - Amazon announced plans to invest up to $50 billion to expand AI and supercomputing capabilities for the US government, with construction set to begin in 2026 [20] - Zhongji Xuchuang's vice president completed a 0.06% share reduction, while Longpan Technology signed a supplementary agreement with Chuangneng New Energy, estimating total sales exceeding 45 billion yuan [20][19]